Full-text resources of PSJD and other databases are now available in the new Library of Science.
Visit https://bibliotekanauki.pl
Preferences help
Polish version English version Language
enabled [disable] Abstract
Number of results

Results found: 4

Number of results on page
first rewind previous Page / 1 next fast forward last

Search results

Search:
in the keywords:  MELANOMA
help Sort By:

help Limit search:
first rewind previous Page / 1 next fast forward last
1

Recent discoveries in the genetics of melanoma and their therapeutic implications

100%
Marquette A., Bagot M., Bensussan A., Dumaz N.
|
|
issue 6
363-372
EN
The incidence of cutaneous malignant melanoma, tumors arising from melanocytes, has increased markedly over the past few years in many countries. Although early melanoma is curable through surgical excision, the prognosis of advanced melanoma is very poor, this tumor being resistant to current therapies. Thus there is a need for new therapies to improve the treatment of advanced melanoma. This review provides an overview of recent discoveries in the genetics of melanoma which could offer new therapeutic opportunities.
2

Cancer-associated retinopathy in patients with breast carcinoma

100%
Misiuk-Hojlo M., Ejma M., Gorczyca W. A., Szymaniec S., Witkowska D., Fortuna W., Miedzybrodzki R., Rogozinska-Szczepka J., Bartnik W.
Archivum Immunologiae et Therapiae Experimentalis
|
2007
|
vol. 55
|
issue 4
247-259
EN
Introduction: Cancer-associated retinopathy (CAR) is a paraneoplastic neurological syndrome resulting in progressive loss of vision and clinical signs of retinal degeneration. It is associated with various types of cancer and is also considered to be an autoimmune disorder that involves cross-reaction between autoantibodies and retinal proteins. The aim of this study was to establish whether immunoreactivity to retinal antigens (RAs) observed in patients with breast cancer is accompanied by any visual impairments. Materials and Methods: Sera of 295 patients with diagnosed breast cancer were screened for the presence of anti-RAs antibodies using immunoblotting. Cellular immunoreactivity to RAs present in retinal extracts and to purified recoverin and arrestin was determined by means of a lymphocyte proliferation assay. Six patients with high-titer antibodies to RAs then underwent ophthalmic and neurological examinations. Results: Four serum samples contained high-titer antibodies to a 46-kDa protein, most probably retinal ?-enolase, three had antibodies to a 48-kDa protein identified as retinal arrestin, while 56-, 43-, 41-, and 34-kDa antigens were recognized only by one serum sample each. Moreover, weak cellular response to all the RAs tested was observed in one patient and another patient responded only to retinal extract. Two of the examined patients displayed symptoms of CAR. Conclusions: Immunoreactivity to RAs in patients with breast cancer may also be present in cases without clinical signs of CAR.
3

Characterization of NO and cytokine release by transplantable melanoma cell lines in relationship to their differentiation

88%
Kozlowska K., Zarzeczna M., Cichorek M.
Archivum Immunologiae et Therapiae Experimentalis
|
2001
|
vol. 49
|
issue 2 suppl.
103
EN
Changes in the secretory activity of two transplantable melanoma lines (differing in many biological features) as regards nitric oxide (NO) and interleukin 6 (IL-6), tumor necrosis factor (TNF-), oncostatin M (OSM) secretion were the subject of the present study. Obtained results show that a spontaneous alteration of the hamster?s native melanoma line in to an amelanotic one is accompanied by a global change of the secretory activity but there was not distinct correlation between the endogenous cytokine secretion and NO secretion by cells of both melanoma lines.
4

Human melanoma gene therapy: from animal studies to clinical trials

75%
Mackiewicz A., Kapcinska M., Laciak M., Malicki J., Murawa P., Nowak, Sibilska E., Wiznerowicz M., Breborowicz D., Lange A., Hawley R. G.
Biotechnologia
|
1996
|
issue 4
42-54
EN
Based on preclinical studies clinical protocol for immuno-gene therapy of human melanoma was designed in our Department.In January 1995, phase I clinical trial was initiated. Until now 5 patients with IV clinical degree of melanoma received geentic vaccine acco9rding to the following schedule: 4 injections in two weeks intervals, 3 injections in one month intervals and 3 injections in two month intervals.During therapy no toxic effects were observed.Induction of specific and non-specific anti-melanoma response was observed.Currently the trial enters phase II. Optimization of doses and immunization schedule as well as verification of patients eliglibility will be carried out.Moreover, clinical effcts of applied therapy will be monitored.
first rewind previous Page / 1 next fast forward last
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.